Skip to main content
SpringerLink
Log in

Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Delamanid exhibited greater in vitro potency than pretomanid against multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) isolates. The pretomanid minimum inhibitory concentration (MIC) values of four MDR-TB isolates were found to be resistant to delamanid ranging from 0.031 to 0.063 mg/L. A novel nonsynonymous mutation within the fbiA gene (Glu249Lys) may be contributing to high-level resistance to delamanid and pretomanid in Mycobacterium tuberculosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denny WA, Palmer BD (2010) The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future Med Chem 2:1295–1304

    Article  CAS  PubMed  Google Scholar 

  2. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P (2015) Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:5316–5323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lee SFK, Laughon BE, Mchugh TD, Lipman M (2019) New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Curr Opin Pulm Med

  4. Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J (2018) Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis (Edinb) 111:20–30

    Article  CAS  Google Scholar 

  5. Manjunatha U, Boshoff HI, Barry CE (2009) The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2:215–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, Li Y, Zhao L, Fu Y, Huang H (2017) In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61

  7. Shi J, Lu J, Wen S, Zong Z, Huo F, Luo J, Liang Q, Li Y, Huang H, Pang Y (2018) In vitro activity of PBTZ169 against multiple Mycobacterium species. Antimicrob Agents Chemother 62

  8. Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, Shashkina E, Kreiswirth BN, Liu Y, Matsumoto M, Geiter L (2016) MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 60:3316–3322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stover CK, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, Mcmurray DN, Kreiswirth BN, Barry CE, Baker WR (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962–966

    Article  CAS  PubMed  Google Scholar 

  10. Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG (2015) In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:136–144

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the staff from the National Clinical Laboratory on Tuberculosis for their technical assistance.

Funding

This study was supported by the Beijing Talents Foundation (2017000021223ZK39), the Beijing Municipal Administration of Hospitals’ Youth Programme (QML20171601), the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20151501 and DFL20181602), and the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201809).

Author information

Author notes

  1. Shu’an Wen, Wei Jing and Tingting Zhang contributed equally to this work.

Authors and Affiliations

  1. National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Institute, Capital Medical University, Beijing, China

    Shu’an Wen, Tingting Zhang, Zhaojing Zong, Yi Xue, Yuanyuan Shang, Fen Wang, Hairong Huang & Yu Pang

  2. Department of Tuberculosis, Beijing Chest Hospital affiliated to Capital Medical University, BeijingTuberculosis and Thoracic Tumor Research Institute, Beijing, China

    Wei Jing & Naihui Chu

Authors
  1. Shu’an Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tingting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaojing Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuanyuan Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hairong Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naihui Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SW, WJ, NC, YP, and HH designed this study. SW, WJ, TZ, ZZ, and YX performed the experiments. SW, WJ, YS, FW, and YP interpreted the data. SW, TZ, NC, YP, and HH wrote the manuscript. All authors approved the final version of the paper.

Corresponding authors

Correspondence to Hairong Huang, Naihui Chu or Yu Pang.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wen, S., Jing, W., Zhang, T. et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 38, 1293–1296 (2019). https://doi.org/10.1007/s10096-019-03551-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-019-03551-w

Keywords

Search

Navigation